



Date: 28th February, 2024

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 Scrip Code: 539872	National Stock Exchange of India Limited 5th Floor, Exchange Plaza, Bandra Kurla Complex Bandra (East) Mumbai-400051 Symbol: BAJAJHCARE
--	---

Dear Sir/Madam,

Sub: Business Updates: Successfully Enters Definitive CDMO Agreement for 15 APIs with UK/EU Customers.

In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, please find attached herewith business updates on successfully entering a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs).

Kindly take the same on record.

Thanking you.

Yours faithfully,

**For and on behalf of Board of Directors of
Bajaj Healthcare Limited**

**Anil Jain
Managing Director
DIN: 00226137**

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604

Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892



CIN: L99999MH1993PLC072892

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West, Mumbai – 400604.

=====

Investor Release

Bajaj Healthcare Limited Enters Definitive CDMO Agreement for 15 APIs with UK/EU Customers

Thane, 28th February 2024. Bajaj Healthcare Ltd. a leading manufacturer of APIs, Intermediates and Formulations, Ltd is delighted to announce that it has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs).

Under this agreement, BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.

Commenting on the above business update, Mr. Anil Jain, Joint Managing Director, Bajaj Healthcare said: *“I am thrilled to share this strategic collaboration which underscores Bajaj Healthcare Ltd.’s commitment to innovation, excellence, and meeting the evolving needs of the pharmaceutical industry. By harnessing our expertise and state-of-the-art infrastructure, we are poised to enhance the accessibility and affordability of essential medications for patients across the globe. Leveraging our cutting-edge in-house Research and Development (R&D) facilities and manufacturing capabilities located at Savli, BHL is poised to deliver exceptional quality and efficiency in meeting our customers’ requirements.*

About Bajaj Healthcare Ltd:

Bajaj Healthcare Limited a leading Manufacturer of APIs, Intermediates and Formulations established in the year 1993. It specialises in the manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-the-art manufacturing facilities of APIs, intermediates, and formulations. These facilities are designed to meet the requirements of both advanced as well as emerging market opportunities. BHL has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.

Contact Details

Bajaj Healthcare Ltd	Investor Relations: Orient Capital
	
CIN: L99999MH1993PLC072892	Mr. Irfan Raean +91 9773778669 Irfan.reen@linkintime.co.in
Name: Mr. Anil Jain, MD	
Email: investors@bajajhealth.com	Mr. Devansh Dedhia +91 9930147479 Devansh.dedhia@linkintime.co.in

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward- looking statements to reflect events or circumstances after the date thereof.